Aflibercept

Revision as of 20:19, 27 September 2011 by WikiBot (talk | contribs) (Protected "Aflibercept": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Aflibercept
Identifiers
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC4318H6788N1164O1304S32
Molar mass96,898.57 g·mol−1

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Aflibercept is a fusion protein under development for the treatment of cancer.

Aflibercept is being co-developed by Sanofi-Aventis and Regeneron Pharmaceuticals. As of 2008, it is currently in phase III clinical trials.

Template:Immunosuppressants


Template:WikiDoc Sources